Form 4: Akebia Therapeutics Director LeAnne M. Zumwalt Reports Stock and Option Grants

Director LeAnne M. Zumwalt reports the acquisition of 30,000 shares of common stock and options to purchase 45,000 shares of Akebia Therapeutics.

Summary

• On June 6, 2024, LeAnne M. Zumwalt, a director of Akebia Therapeutics, Inc., was granted 30,000 shares of common stock as restricted stock units (RSUs).
• These RSUs will vest fully on the first anniversary of the grant date or earlier, prior to the first annual meeting of stockholders after the grant date, contingent upon continued service to the Issuer.
• Zumwalt also received an option to purchase 45,000 shares of Akebia's common stock at an exercise price of $1.07.
• This stock option will vest and become exercisable in full on the first anniversary of the grant date or earlier, prior to the first annual meeting of stockholders after the grant date, contingent upon continued service to the Issuer.
• Following these transactions, Zumwalt beneficially owns 73,700 shares of Akebia Therapeutics common stock and options to purchase 45,000 shares.
• These grants were made pursuant to Akebia's 2023 Stock Incentive Plan and the Third Amended and Restated Non-Employee Director Compensation Program.

Sentiment

Score: 7

Explanation: The document reflects standard compensation practices. The sentiment is neutral to slightly positive as it aligns director interests with shareholders.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

This is a standard practice for compensating board members in publicly traded companies, aligning their interests with shareholders through equity-based compensation.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and grant sizes are generally comparable to industry norms, designed to incentivize long-term commitment and alignment with shareholder value.

Stakeholder Impact

• Shareholders: Aligns director's interests with shareholder value through equity ownership.
• Employees: Reinforces the company's commitment to incentivizing key personnel.
• Company: Helps retain and motivate a key member of the board of directors.

Key Dates